Preoperative imaging studies, such as magnetic resonance imaging (MRI) of the anal canal and/or endoanal ultrasonography, can help identify abscesses which are sometimes smaller and deeper, but symptomatic. They can also delimit the location of the abscesses in relation to the anal sphincters and the involved portion of the anal canal. 2 Additionally, these exams allow the identification of the course of perianal fistulas, showing the degree of involvement of the sphincter muscles. Endoanal ultrasonography is limited in cases of severe stenosis of the anal canal, which makes it impossible to introduce the device.
Perineal examination under anesthesia and surgical procedures should consist of draining abscesses and exploration of fistulas by placing seton, which can remain for a long period. Fistulotomy without repairs should be restricted to very shallow paths that do not compromise the sphincter muscles. Another option to consider is the endorectal advancement flap, which has been used in the treatment of complex or recurrent fistulas, and healing is observed in 60-70% of CD patients. 3 The use of fibrin glue in the treatment of CD perianal fistula showed efficacy in the treatment of complex fistulas, but no advantages in the case of simple fistulas when compared to conventional treatment. 4 Fibrin glue seems to be less effective in patients with CD, but is well tolerated and has a minimal risk profile, and could be used to avoid further surgery or as an alternative to long-term seton placement. The fistula plug is another treatment option that has been studied for perianal fistula. It is a portion of lyophilized porcine intestinal submucosa and acts as a collagen scaffold, which is filled by endogenous cells. Reported healing rates were 54.3% in CD patients at follow-up between 3 and 24 months, which did not differ from patients without CD. The extrusion of the plug is the main reason for secondary failure of this technique. 5 Mesenchymal stem cell (MSC) therapy for CD represents a promising strategy and has been studied for luminal disease. 6 To assess the efficacy of MSCs for CD-related fistulas, the ADMIRE-Crohn's disease multicentre study is underway (http://www.clinicaltrials.gov/ct2/show/NCT01541579). This protocol evaluates the use of adipose derived mesenchymal stem cells (administered by intralesional injection) for induction of remission in perianal fistulizing CD, and the estimated primary completion date is the beginning of the next year with promising results. The main advantage of this technique is the sphincter preservation, avoiding repairs or fistulotomy.
Not infrequently, perianal fistulas are accompanied by extensive CD involvement of the rectum, which can lead to loss of the rectum and anal canal, exhausting even the best in clinical therapy, requiring proctectomy and permanent ostomy.
In summary, perianal CD is a common manifestation of the disease and if it is concomitant to rectal lesions, the clinical and surgical management may become complex. Despite all developed drugs and new surgical techniques, there is a failure rate that is not negligible. Some cell therapies, such as MSCs, and new drugs that act upon other specific immune targets may be promising treatments for complex and/or recurrent fistulazing CD in the future.
